Fibrate-statin combinations with reduced fed-fasted effects
US6534088B2 · kind B2 · utility
16Cited by
1References
101Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 20, 2001 |
| Grant date | Mar 18, 2003 |
| Priority date | — |
| Expiry date | Apr 20, 2021 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/906
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention discloses an orally administered pharmaceutical composition for the treatment of elevated levels of cholesterol and related conditions comprising a statin and fenofibrate in the form of microparticles of solid fenofibrate that are stabilized by phospholipid as a surface active substance, wherein a therapeutically effective amount of the composition provides the statin and a quantity of fenofibrate to a fasted human patient that is greater than 80% of the quantity of fenofibrate provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.